miR-10b Inhibition: A strategy for treating metastatic breast cancer.

A research paper published in Oncotarget discusses the development of a nanodrug called MN-anti-miR10b, which delivers anti-miR-10b antisense oligomers to cancer cells. The paper highlights the poor prognosis for metastatic breast cancer and the role of miR-10b in driving metastasis. The researchers found that inhibiting miR-10b with MN-anti-miR10b activates developmental processes in cancer cells and decreases their stemness. In mouse models, MN-anti-miR10b was shown to prevent the onset of metastasis and eliminate existing metastases when combined with chemotherapy. The study suggests that MN-anti-miR10b could be a potential therapy for metastatic breast cancer. [Extracted from the article]